EWPI Emerging World Pharma Inc (CE)

Emerging World Pharma Inc. (PINKSHEETS: EWPI), an investor in generic based pharmaceutical companies manufacturing within developing nations, announces that African Global Pharma Ghana Ltd has formed an exclusive marketing and distribution agreement with the Catholic Diocese of Sunyani, Ghana. Emerging World Pharma had earlier provided an investment into African Global Pharma and has an option to increase their investment and percentage of profits by up to 25%.

The Diocese of Sunyani will be the sole distributor for all the drugs manufactured by African Global Pharma Ghana Ltd. This strategic partnership will allow priority access to Catholic Mission Hospitals in Ghana, West Africa and the rest of the African continent.

African Global Pharma will produce a variety of medicines including, antibiotics and anti-malarials. There are a total of thirteen different medicines to begin production with a further eighteen to be registered later on as production capacity is expanded.

The Diocese of Sunyani will also market AGP products to other private and public hospitals and pharmacies. Ghana acts as the gateway to a huge sub-regional market of over 250 million people.

The partnership will also include the eventual opening of a research facility to be determined and approved by the board at the University of the Diocese. The focus will be on the research and development for new medicines and for the training of students in this pharmacological field.

Emerging World Pharma company president, Brandon Keks is returning to Africa this week to further assess progress of the generic drug manufacturing facilities and to continue business relations with African Global Pharma Inc. "I am told that the production facilities are right on schedule and that equipment will be set up and test runs will begin in the next few weeks," added Keks.

www.emergingpharma.com

About Emerging World Pharma Inc.

Emerging World Pharma Inc. is an investor in generic based pharmaceutical companies manufacturing within developing nations.

The company focuses its investments on generic pharmaceutical companies that have contracts with three major buyer groups; church, government and wholesalers. Market research shows that these branches are the most secure, protected and reputable for the distribution of medicines.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.

Contact: Joel Everret Emerging World Pharma Inc. Investor Relations Division 703-646-2633 Email: info@emergingpharma.com